Heymann Devorah, Vidal Liat, Or Yuval, Shoham Zeev
Department of Obstetrics and Gynaecology, Kaplan Medical Center, Rehovot, Israel.
Syneos Health, Tel Aviv, Israel.
Cochrane Database Syst Rev. 2020 Sep 2;9(9):CD007421. doi: 10.1002/14651858.CD007421.pub4.
This is an update of a Cochrane Review first published in the Cochrane Library (2010, Issue 7). To increase the success rate of assisted reproductive technologies (ARTs), adherence compounds such as hyaluronic acid (HA) have been introduced into subfertility management. Adherence compounds are added to the embryo transfer medium to increase the likelihood of embryo implantation, with the potential for higher clinical pregnancy and live birth rates.
To determine whether adding adherence compounds to embryo transfer media could improve pregnancy outcomes, including improving live birth and decreasing miscarriage, in women undergoing assisted reproduction.
We searched the Cochrane Gynaecology and Fertility Group Trials Register, CENTRAL, MEDLINE, Embase, and PsycINFO electronic databases on 7 January 2020 for randomised controlled trials that examined the effects of adherence compounds in embryo transfer media on pregnancy outcomes. Furthermore, we communicated with experts in the field, searched trials registries, checked reference lists of relevant studies, and conference abstracts were handsearched.
Only truly randomised controlled trials comparing embryo transfer media containing functional concentrations of adherence compounds to media with no or low adherence compound concentrations were included.
Two review authors selected trials for inclusion according to the above criteria, after which the same two review authors independently extracted data for subsequent analysis. Statistical analysis was performed according to the guidelines developed by Cochrane. We combined data to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity using the I² statistic. We used GRADE methods to assess the overall quality of evidence for the main comparisons.
We analysed 26 studies with a total of 6704 participants. Overall, the certainty of evidence was low to moderate: the main limitations were imprecision and/or heterogeneity. Compared to embryos transferred in media containing no or low (0.125 mg/mL) HA, the addition of functional (0.5 mg/mL) HA concentrations to the transfer media probably increases the live birth rate (RR 1.21, 95% CI 1.1 to 1.31; 10 RCTs, N = 4066; I² = 33%; moderate-quality evidence). This suggests that if the chance of live birth following no HA addition in media is assumed to be 33%, the chance following HA addition would be between 37% and 44%. The addition of HA may slightly decrease miscarriage rates (RR 0.82, 95% CI 0.67 to 1.00; 7 RCTs, N = 3091; I² = 66%; low-quality evidence). Nevertheless, when only studies with low risk of bias were included in the analysis, there was no conclusive evidence of a difference in miscarriage rates (RR 0.96, 95% CI 0.75 to 1.23; N = 2219; I² = 36%). Adding HA to transfer media probably results in an increase in both clinical pregnancy (RR 1.16, 95% CI 1.09 to 1.23; 17 studies, N = 5247; I² = 40%; moderate-quality evidence) and multiple pregnancy rates (RR 1.45, 95% CI 1.24 to 1.70; 7 studies, N = 3337; I² = 36%; moderate-quality evidence). We are uncertain of the effect of HA added to transfer media on the rate of total adverse events (RR 0.86, 95% CI 0.40 to 1.84; 3 studies, N = 1487; I² = 0%; low-quality evidence).
AUTHORS' CONCLUSIONS: Moderate-quality evidence shows improved clinical pregnancy and live birth rates with the addition of HA as an adherence compound in embryo transfer media in ART. Low-quality evidence suggests that adding HA may slightly decrease miscarriage rates, but when only studies at low risk of bias were included in the analysis, the results were inconclusive. HA had no clear effect on the rate of total adverse events. The increase in multiple pregnancy rates may be due to combining an adherence compound and transferring more than one embryo. Further studies of adherence compounds with single embryo transfer need to be undertaken.
这是对首次发表于《考克兰系统评价》(2010年第7期)的考克兰综述的更新。为提高辅助生殖技术(ART)的成功率,诸如透明质酸(HA)等黏附化合物已被引入到不孕症管理中。黏附化合物被添加到胚胎移植培养基中,以增加胚胎着床的可能性,从而有可能提高临床妊娠率和活产率。
确定在胚胎移植培养基中添加黏附化合物是否能改善接受辅助生殖的女性的妊娠结局,包括提高活产率和降低流产率。
我们于2020年1月7日检索了考克兰妇科与生育组试验注册库、CENTRAL、MEDLINE、Embase和PsycINFO电子数据库,以查找检验胚胎移植培养基中黏附化合物对妊娠结局影响的随机对照试验。此外,我们与该领域的专家进行了交流,检索了试验注册库,查阅了相关研究的参考文献列表,并手工检索了会议摘要。
仅纳入将含有功能浓度黏附化合物的胚胎移植培养基与不含或低黏附化合物浓度的培养基进行比较的真正随机对照试验。
两位综述作者根据上述标准选择纳入试验,之后同样由这两位综述作者独立提取数据以供后续分析。根据考克兰制定的指南进行统计分析。我们合并数据以计算合并风险比(RRs)和95%置信区间(CIs)。我们使用I²统计量评估统计异质性。我们使用GRADE方法评估主要比较的总体证据质量。
我们分析了26项研究,共6704名参与者。总体而言,证据的确定性为低到中等:主要局限性是不精确和/或异质性。与在不含或低(0.125 mg/mL)HA的培养基中移植的胚胎相比,在移植培养基中添加功能浓度(0.5 mg/mL)的HA可能会提高活产率(RR 1.21,95% CI 1.1至1.31;10项随机对照试验,N = 4066;I² = 33%;中等质量证据)。这表明,如果假设在培养基中不添加HA时活产的几率为33%,那么添加HA后的几率将在37%至44%之间。添加HA可能会略微降低流产率(RR 0.82,95% CI 0.67至1.00;7项随机对照试验,N = 3091;I² = 66%;低质量证据)。然而,当仅将偏倚风险低的研究纳入分析时,没有确凿证据表明流产率存在差异(RR 0.96,95% CI 0.75至1.23;N = 2219;I² = 36%)。在移植培养基中添加HA可能会导致临床妊娠率(RR 1.16,95% CI 1.09至1.23;17项研究,N = 5247;I² = 40%;中等质量证据)和多胎妊娠率(RR 1.45,95% CI 1.24至1.70;7项研究,N = 3337;I² = 36%;中等质量证据)均增加。我们不确定添加到移植培养基中的HA对总不良事件发生率的影响(RR 0.86,95% CI 0.40至1.84;3项研究,N = 1487;I² = 0%;低质量证据)。
中等质量证据表明,在ART的胚胎移植培养基中添加HA作为黏附化合物可提高临床妊娠率和活产率。低质量证据表明添加HA可能会略微降低流产率,但当仅将偏倚风险低的研究纳入分析时,结果尚无定论。HA对总不良事件发生率没有明确影响。多胎妊娠率的增加可能是由于将黏附化合物与移植多个胚胎相结合。需要对单胚胎移植的黏附化合物进行进一步研究。